Published in Head Neck on February 01, 2007
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res (2013) 1.87
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck (2011) 1.45
ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34
Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.26
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer (2011) 1.21
The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol (2006) 1.20
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res (2011) 1.15
Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother (2010) 1.15
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther (2008) 1.15
Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res (2008) 1.14
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol (2009) 1.13
Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol (2012) 1.11
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther (2009) 1.08
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle (2013) 1.04
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Lett (2011) 1.03
Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature. Oral Oncol (2007) 1.02
Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother (2009) 1.01
Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia (2007) 1.00
Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol (2010) 0.97
Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma. Clin Cancer Res (2011) 0.95
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics (2011) 0.95
MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS One (2013) 0.95
Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget (2015) 0.94
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res (2012) 0.94
Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer (2016) 0.93
Human β-defensin 3 promotes NF-κB-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck. Carcinogenesis (2010) 0.93
Establishment and Molecular Cytogenetic Characterization of a Cell Culture Model of Head and Neck Squamous Cell Carcinoma (HNSCC). Genes (Basel) (2010) 0.92
Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res (2008) 0.92
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther (2012) 0.90
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol (2012) 0.89
Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck (2014) 0.89
Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. Cancer Res (2011) 0.87
PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol (2012) 0.87
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS One (2013) 0.85
Integrative genomics in combination with RNA interference identifies prognostic and functionally relevant gene targets for oral squamous cell carcinoma. PLoS Genet (2013) 0.84
Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. Int J Cancer (2009) 0.84
Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo. Otolaryngol Head Neck Surg (2012) 0.83
High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma. Cancer Res (2015) 0.83
Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol (2014) 0.83
USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics. Oral Oncol (2011) 0.83
STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells. Mol Cancer Ther (2015) 0.82
In vitro cytokine release profile: predictive value for metastatic potential in head and neck squamous cell carcinomas. Head Neck (2013) 0.82
Ubiquitination of human AP-endonuclease 1 (APE1) enhanced by T233E substitution and by CDK5. Nucleic Acids Res (2011) 0.82
Establishment and genetic characterization of six unique tumor cell lines as preclinical models for sinonasal squamous cell carcinoma. Sci Rep (2014) 0.81
Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med (2013) 0.81
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget (2016) 0.81
Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. Am J Cancer Res (2015) 0.81
Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. PLoS One (2013) 0.81
Establishment and characterization of novel cell lines from sinonasal undifferentiated carcinoma. Clin Cancer Res (2012) 0.81
Integrative molecular characterization of head and neck cancer cell model genomes. Head Neck (2010) 0.81
Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. Oncotarget (2016) 0.79
Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol (2014) 0.79
Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalk. Oncotarget (2014) 0.78
Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models. ACS Chem Biol (2012) 0.78
Suppression of oxidative phosphorylation in mouse embryonic fibroblast cells deficient in apurinic/apyrimidinic endonuclease. DNA Repair (Amst) (2015) 0.78
UM-SCC-103: a unique tongue cancer cell line that recapitulates the tumorigenic stem cell population of the primary tumor. Ann Otol Rhinol Laryngol (2014) 0.78
Dyskerin localizes to the mitotic apparatus and is required for orderly mitosis in human cells. PLoS One (2013) 0.78
Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties. Carcinogenesis (2015) 0.77
A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma. Oncotarget (2011) 0.77
Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer (2014) 0.77
Ethical and technical considerations for the creation of cell lines in the head & neck and tissue harvesting for research and drug development (Part II): ethical aspects of obtaining tissue specimens. Int Arch Med (2009) 0.77
Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg (2015) 0.77
Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G₂ delay and mitotic defects. Sci Rep (2013) 0.77
Alpha-2 Heremans Schmid Glycoprotein (AHSG) modulates signaling pathways in head and neck squamous cell carcinoma cell line SQ20B. Exp Cell Res (2013) 0.76
Human papillomavirus 16 (HPV16) enhances tumor growth and cancer stemness of HPV-negative oral/oropharyngeal squamous cell carcinoma cells via miR-181 regulation. Papillomavirus Res (2015) 0.76
Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck (2015) 0.76
Orai1 promotes tumor progression by enhancing cancer stemness via NFAT signaling in oral/oropharyngeal squamous cell carcinoma. Oncotarget (2016) 0.76
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade. PLoS One (2014) 0.76
Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. J Immunol (2016) 0.76
Mathematical model of the effect of intercellular cooperative interactions in cancer during drug therapy. Annu ORNL Biomed Sci Eng Cent Conf (2013) 0.75
Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma. Am J Pathol (2016) 0.75
Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas. J Cell Physiol (2016) 0.75
Novel antioxidants are not toxic to normal tissues but effectively kill cancer cells. Cancer Biol Ther (2013) 0.75
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel) (2017) 0.75
Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review. Cancers (Basel) (2015) 0.75
Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. Cancer Immunol Immunother (2016) 0.75
Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases. J Cell Physiol (2017) 0.75
miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin. Am J Pathol (2017) 0.75
Establishment of oral squamous cell carcinoma cell line and magnetic bead-based isolation and characterization of its CD90/CD44 subpopulations. Oncotarget (2017) 0.75
HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation. Oncotarget (2017) 0.75
Cytotoxic Effect of Thiabendazole on Hn5 Head and Neck Squamous Cell Carcinoma Cell Line. J Dent (Shiraz) (2017) 0.75
Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor. Oncotarget (2017) 0.75
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Head and neck cancer. Lancet (2008) 6.33
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 3.67
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc (2010) 3.44
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Spindle multipolarity is prevented by centrosomal clustering. Science (2005) 3.10
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res (2005) 2.97
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
A shifting paradigm for patients with head and neck cancer: transoral robotic surgery (TORS). Oncology (Williston Park) (2010) 2.81
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett (2008) 2.55
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck (2010) 2.51
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol (2010) 2.41
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 2.30
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) (2010) 2.22
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer (2006) 2.16
Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res (2010) 2.11
STAT-mediated EGFR signaling in cancer. J Cell Biochem (2007) 2.05
Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res (2002) 2.05
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res (2012) 1.98
Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer (2009) 1.98
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck (2008) 1.97
STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 1.95
Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One (2010) 1.94
Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol Res (2006) 1.91
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res (2009) 1.85
Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.85
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.85
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol (2009) 1.79
T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res (2003) 1.79
Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res (2005) 1.73
Resolution of anaphase bridges in cancer cells. Chromosoma (2004) 1.72
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther (2005) 1.70
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 1.69
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods (2009) 1.69
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res (2009) 1.66
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol (2009) 1.64
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res (2008) 1.63
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. Clin Cancer Res (2007) 1.62
Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res (2007) 1.61
Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells. Cancer Res (2006) 1.60
The impact of health insurance status on the survival of patients with head and neck cancer. Cancer (2010) 1.58
Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A (2005) 1.57
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid (2012) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene (2005) 1.56
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia (2006) 1.55
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer (2010) 1.53
Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol (2012) 1.53
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51
Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci (2008) 1.50
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol (2006) 1.49
Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and synteny to the 7F5 amplicon in murine oral carcinoma. Genes Chromosomes Cancer (2006) 1.49
A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res (2008) 1.48